China Jo-Jo Drugstores, Inc. Reports Fiscal Year 2012 Earnings Results And Schedules Conference Call For July 3, 2012
“As we look to Fiscal 2013, we look to growing our revenue through our retail and wholesale operations while remaining focused on bottom line results,” concluded Mr. Liu.
Balance Sheet Highlights
As of March 31, 2012, the Company had $3.8 million of cash, $74.9 million in total assets and $22.6 million in total liabilities.
Fiscal Year 2012 Full Year Results
The following table summarizes our results of operations for the fiscal years ended March 31, 2012 and 2011.| Years Ended March 31, | ||||||||||||||||||||
| 2012 | 2011 | |||||||||||||||||||
| Amount | Percentage of total revenue | Amount | Percentage of total revenue | |||||||||||||||||
| Revenues | $ | 94,352,885 | 100.0 | % | $ | 69,969,479 | 100.0 | % | ||||||||||||
| Gross Profit | $ | 27,562,801 | 29.2 | % | $ | 21,142,094 | 30.2 | % | ||||||||||||
| Selling Expenses | $ | 8,498,240 | 9.0 | % | $ | 4,838,745 | 6.9 | % | ||||||||||||
| General and Administrative Expenses | $ | 8,582,389 | 9.1 | % | $ | 4,723,943 | 6.8 | % | ||||||||||||
| Income from Operations | $ | 10,482,172 | 11.1 | % | $ | 11,579,406 | 16.5 | % | ||||||||||||
| Other Income (Expense) | $ | 187,865 | 0.2 | % | $ | 127,172 | 0.2 | % | ||||||||||||
| Changes in Fair Value of Purchase Option Derivative Liability | $ | 118,807 | 0.1 | % | $ | 249,225 | 0.4 | % | ||||||||||||
| Income Tax Expenses | $ | 2,648,365 | 2.8 | % | $ | 3,523,345 | 5.0 | % | ||||||||||||
| Net Income | $ | 8,140,479 | 8.6 | % | $ | 8,432,458 | 12.1 | % | ||||||||||||
| (1) | During fiscal 2012, we opened several new “Jiuzhou Grand Pharmacy” drugstores and also started to expand our online drug sales. Our retail store count increased to 61 as of March 31, 2012, from 53 stores a year ago. The increased number of stores brought new opportunities to sell our products and services to retail customers. Retail sales accounted for about 70% of our total revenue for the year ended March 31, 2012. Same-store sales decreased by approximately $7.0 million or 10.1%, while our new stores contributed approximately $3.1 million to our revenue. We expect same-store sales will continue to decline as the frequency of government-mandated price controls and the number of drugs subject to price controls continue to rise and, to a lesser extent, with the shift of our group sales to our wholesale business. |
| (2) | We started our wholesale business after acquiring Jiuxin Medicine in August 2011, through which we have been distributing third-party pharmaceutical and healthcare products to pharmaceutical trading companies and other group customers. In the fourth quarter of fiscal 2012, we also began distributing the TCM herbs that we have been cultivating, also to third-party pharmaceutical trading companies. Our wholesale business increased rapidly during fiscal 2012 because we introduced very competitive pricing to customers to stimulate sales. Sales from the wholesale business accounted for about 30% of our total revenue for the fiscal year ended March 31, 2012. |
| For the year endedMarch 31, 2012 | For the year endedMarch 31, 2011 | |||||||||||||||||||||||||||
| Amount | % of totalrevenue | Amount | % of totalrevenue | Variance byamount | % of change | |||||||||||||||||||||||
| Revenue from retail business | ||||||||||||||||||||||||||||
| Revenue from drugstores | $ | 64,981,643 | 69 | % | $ | 66,477,736 | 95 | % | $ | (1,496,093 | ) | (2 | )% | |||||||||||||||
| Revenue from liquor sales | - | - | 3,491,743 | 5 | % | (3,491,743 | ) | (100 | )% | |||||||||||||||||||
| Revenue from online sales | 1,092,705 | 1 | % | - | 0 | % | 1,092,705 | 100 | % | |||||||||||||||||||
| Sub-total of retail revenue | 66,074,348 | 70 | % | 69,969,479 | 100 | % | (3,895,131 | ) | (6 | )% | ||||||||||||||||||
| Revenue from wholesale business | ||||||||||||||||||||||||||||
| Revenue from Jiuxin Medicine | 24,060,963 | 26 | % | - | 0 | % | 24,060,963 | 100 | % | |||||||||||||||||||
| Revenue from harvested TCM herbs | 4,217,574 | 4 | % | - | 0 | % | 4,217,574 | 100 | % | |||||||||||||||||||
| Sub-total of wholesale revenue | 28,278,537 | 30 | % | - | 0 | % | 28,278,537 | 100 | % | |||||||||||||||||||
| Total revenue | $ | 94,352,885 | 100 | % | $ | 69,969,479 | 100 | % | $ | 24,383,406 | 35 | % | ||||||||||||||||
| (1) | Revenue from ”Jiuzhou Grand Pharmacy” stores decreased by approximately $3.9 million or 6% year over year, mainly due to two reasons. Since the second quarter of 2011, the Hangzhou government has been gradually restricting retail drugstores within the city from organizing large-scale marketing promotions on the streets to give further rebate or discount to customers making purchases with government-sponsored medical insurance card. Our promotional activities were curtailed accordingly, which impacted our retail sales revenue, especially from sales of certain prescription drugs covered by the medical insurance card. In addition, the government subjected more drugs to price control in October 2011, which caused us to reduce prices for some of the affected drugs and stop carrying others at our pharmacies, which especially impacted our revenue for the three months ended March 31, 2012. |
| (2) | The decrease in retail revenue was also affected by the relocation of three retail stores due to building demolishment ordered by the local government. As a result of the time lost to relocating to and readying the new store locations, sales from these three stores were down for the fiscal year ended March 31, 2012. |
| (3) | Another factor for the decreased retail revenue is the shift of group sales from Jiuzhou Pharmacy’s retail business to Jiuxin Medicine’s wholesales business. We originally recorded group sales under Jiuzhou Pharmacy’s retail system in the prior year. But starting in August 2011, such sales have been recorded under Jiuxin Medicine’s wholesale system because we believe group sales are essentially wholesale in nature. Accordingly, $15.5 million in group sales that would have otherwise been recorded under Jiuzhou Pharmacy have now been recorded under Jiuxin Medicine, including $8.9 million during the fourth quarter of fiscal 2012. Such internal re-allocation of sales revenue between our retail and wholesale businesses affected the comparison of our retail sales for fiscal 2012 versus fiscal 2011, but has no impact on our consolidated financial statements. |
| Year ended March 31, | Variance by | % of | |||||||||||||||
| 2012 | 2011 | amount | change | ||||||||||||||
| Revenue from retail business | |||||||||||||||||
| First quarter ended June 30, 2011 | 21,427,859 | 15,207,428 | 6,220,431 | 41 | % | ||||||||||||
| Second quarter ended September 30, 2011 | 18,799,919 | 15,678,170 | 3,121,749 | 20 | % | ||||||||||||
| Third quarter ended December 31,2011 | 18,123,907 | 18,042,309 | 81,598 | 0 | % | ||||||||||||
| Fourth quarter ended March 31, 2012 | 7,722,663 | 21,041,572 | (13,318,909 | ) | (63 | )% | |||||||||||
| Total revenue from retail business | 66,074,348 | 69,969,479 | (3,895,131 | ) | (6 | )% | |||||||||||
| Revenue from wholesale business | |||||||||||||||||
| First quarter ended June 30, 2011 | - | - | - | N/A | |||||||||||||
| Second quarter ended September 30, 2011 | 3,425,028 | - | 3,425,028 | N/A | |||||||||||||
| Third quarter ended December 31, 2011 | 7,520,042 | - | 7,520,042 | N/A | |||||||||||||
| Fourth quarter ended March 31, 2012 | 17,333,467 | - | 17,333,467 | N/A | |||||||||||||
| Total revenue from wholesale business | 28,278,537 | - | 28,278,537 | N/A | |||||||||||||
| Total revenue | $ | 94,352,885 | $ | 69,969,479 | $ | 24,383,406 | 35 | % | |||||||||
Select the service that is right for you!
COMPARE ALL SERVICESAction Alerts PLUS
TRY IT FREEJim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
Product Features:
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Dividend Stock Advisor
TRY IT FREENew! $49.95/yr
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
Product Features:
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Stocks Under $10
TRY IT FREEDavid Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.
Product Features:
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
- Weekly roundups
Real Money
TRY IT FREE24/7 market commentary from Jim Cramer and 20+ veteran Wall Street gurus. Get access to the latest trading ideas on stocks, options, and ETFs as well as a real-time forum to see the pros exchanging their investment ideas.
Product Features:
- Jim Cramer + 20 Wall Street pros
- Intraday commentary & news
- Real-time trading forum
- Actionable trade ideas
Real Money Pro
TRY IT FREEAll of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
Product Features:
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Options Profits
TRY IT FREEOur options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
Product Features:
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV
